Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection. - 2ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension
- 3Moving Pool Highlights for 2024
- 4WHO suspends medical evacuations from Gaza following death of contractor in 'security incident'
- 5How Much Has the Iran War Cost the Average American Per Day?
- Family Holiday spots
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Former Israeli judge does not expect Netanyahu to be pardoned
- NASA releases stunning new images captured by the Artemis II moon mission, including 'Earthset' and a solar eclipse from space
- Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
- Deadly attack on kindergarten reported in Sudan
- 6 Vehicle Rental Administrations: Pick Your Ideal Ride
- Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential
